CP
CTXR icon

Corbenic Partners’s Citius Pharmaceuticals CTXR Stock Holding History

Corbenic Partners’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-72
Closed -$6K – 283
2021
Q2 		$6K Hold
72
– – ﹤0.01% 201
2021
Q1 		$3K Hold
72
– – ﹤0.01% 211
2020
Q4 		$2K Hold
72
– – ﹤0.01% 175
2020
Q3 		$2K Hold
72
– – ﹤0.01% 145
2020
Q2 		$2K Hold
72
– – ﹤0.01% 137
2020
Q1 		$1K Hold
72
– – ﹤0.01% 168
2019
Q4 		$2K Buy
+72
New +$1.05K ﹤0.01% 158
2017
Q4 		$7K Hold
72
– – 0.01% 144
2017
Q3 		$6K Buy
+72
New +$5.61K 0.01% 181

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Corbenic Partners's CTXR Position: Q3 2021 in Review

Corbenic Partners sold out of Citius Pharmaceuticals (CTXR) in Q3 2021, closing a stake of 72 shares — an estimated $6K sold.

Corbenic Partners first reported a position in CTXR in Q3 2017 and held it in 9 quarters. The position peaked at $7K in Q4 2017. 71 funds tracked by Wall St. Rank hold CTXR as of Q3 2021.

  • Corbenic Partners reported no remaining Citius Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Corbenic Partners sold 72 Citius Pharmaceuticals shares in Q3 2021, an estimated $6K.
  • Corbenic Partners first reported a position in Citius Pharmaceuticals in Q3 2017 and held it in 9 quarters.
  • Corbenic Partners's Citius Pharmaceuticals position peaked at $7K in Q4 2017.
  • 71 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2021.

Based on Corbenic Partners's 13F filing for Q3 2021, filed 13 Oct 2021.